Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical IL-1-Ra for Corneal Neovascularization
NCT00915590Phase 2Terminated
- Start
- Apr 2009
- Primary completion
- Mar 2011
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of anakinra in corneal neovascularization (CNV). Primary endpoints: Incidence and Severity of Ocular Adverse Event at 64 weeks and Extent of Neovascular Area at 64 weeks. Started Apr 2009; status: terminated.
02
Drugs
anakinra
03
Conditions
corneal neovascularization (CNV)
Beyond the preview
Go deeper on NCT00915590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00915590.